Cytidine 5'-diphosphocholine has been widely studied in systemic neurodegenerative diseases, like Alzheimer's disease, Parkinson's disease, and brain ischemia. The rationale for the use of citicoline in ophthalmological neurodegenerative diseases, including glaucoma, anterior ischemic optic neuropathy, and diabetic retinopathy, is founded on its multifactorial mechanism of action and the involvement in several metabolic pathways, including phospholipid homeostasis, mitochondrial dynamics, as well as cholinergic and dopaminergic transmission, all being involved in the complexity of the visual transmission. This narrative review is aimed at reporting both pre-clinical data regarding the involvement of citicoline in such metabolic pathways (including new insights about its role in the intracellular proteostasis through an interaction with the proteasome) and its effects on clinical psychophysical, electrophysiological, and morphological outcomes following its use in ophthalmological neurodegenerative diseases (including the results of the most recent prospective randomized clinical trials).

Oddone, F., Rossetti, L., Parravano, M., Sbardella, D., Coletta, M., Ziccardi, L., et al. (2021). Citicoline in ophthalmological neurodegenerative disease: A comprehensive review. PHARMACEUTICALS, 14(3), 281 [10.3390/ph14030281].

Citicoline in ophthalmological neurodegenerative disease: A comprehensive review

Coletta M.;Manni G.;
2021-01-01

Abstract

Cytidine 5'-diphosphocholine has been widely studied in systemic neurodegenerative diseases, like Alzheimer's disease, Parkinson's disease, and brain ischemia. The rationale for the use of citicoline in ophthalmological neurodegenerative diseases, including glaucoma, anterior ischemic optic neuropathy, and diabetic retinopathy, is founded on its multifactorial mechanism of action and the involvement in several metabolic pathways, including phospholipid homeostasis, mitochondrial dynamics, as well as cholinergic and dopaminergic transmission, all being involved in the complexity of the visual transmission. This narrative review is aimed at reporting both pre-clinical data regarding the involvement of citicoline in such metabolic pathways (including new insights about its role in the intracellular proteostasis through an interaction with the proteasome) and its effects on clinical psychophysical, electrophysiological, and morphological outcomes following its use in ophthalmological neurodegenerative diseases (including the results of the most recent prospective randomized clinical trials).
2021
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore BIO/10 - BIOCHIMICA
English
Con Impact Factor ISI
apoptosis
citicoline
diabetic retinopathy
glaucoma
ischemic optic neuropathy
neurodegeneration
neuroprotection
proteasome
retinal ganglion cells
Oddone, F., Rossetti, L., Parravano, M., Sbardella, D., Coletta, M., Ziccardi, L., et al. (2021). Citicoline in ophthalmological neurodegenerative disease: A comprehensive review. PHARMACEUTICALS, 14(3), 281 [10.3390/ph14030281].
Oddone, F; Rossetti, L; Parravano, M; Sbardella, D; Coletta, M; Ziccardi, L; Roberti, G; Carnevale, C; Romano, D; Manni, G; Parisi, V
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
pharmaceuticals-2021.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Non specificato
Dimensione 523.74 kB
Formato Adobe PDF
523.74 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/279467
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 13
social impact